logo
Malaysia launches MYMT 2026 campaign to attract high-value health travellers

Malaysia launches MYMT 2026 campaign to attract high-value health travellers

The Sun6 days ago
Dzulkefly (centre) launching Malaysia Year of Medical Tourism 2026 at the Malaysia International Trade and Exhibition Centre today. Second from left is Health Ministry secretary-general Datuk Seri Suriani Ahmad. – Bernamapic
KUALA LUMPUR: Malaysia is doubling down on its ambition to become one of Asia's top medical tourism hubs, and banking on the Malaysia Year of Medical Tourism 2026 (MYMT 2026) campaign to draw more high-value health travellers while ensuring affordability and inclusivity remain central to its strategy.
Health Minister Datuk Seri Dr Dzulkefly Ahmad, who launched the campaign today at the Malaysia International Trade and Exhibition Centre, said Malaysia's unique value proposition, world-class medical facilities, competitive costs and culturally attuned hospitality, positions it strongly against regional heavyweights Thailand and Singapore.
'When we do our peer comparison regionally, we still believe we are competitive. That is our fighting spirit,' Dzulkefly told reporters during a post-launch press conference.
Addressing industry worries about the impact of the 6% Sales and Service Tax on healthcare packages, Dzulkefly acknowledged the concern but insisted Malaysia retains a pricing advantage compared to its neighbours.
'Whatever it is, it will leave an impression,' he said.
'But we still feel, even with the SST, Malaysia remains competitive in the region.'
Malaysia attracted 1.6 million healthcare travellers in 2024, with the bulk coming from Indonesia, India and China.
Dzulkefly said while Indonesia would remain the largest market, MYMT 2026 will aim to diversify catchment markets to reduce reliance on traditional sources and tap new segments in the Middle East and Europe.
'We will continue to grow, not just depending on the three countries mentioned earlier,' he said. 'There is a pull factor we can create for other markets.'
Dzulkefly highlighted cardiothoracic surgery, in-vitro fertilisation and oncology as Malaysia's flagship specialties, while also pushing traditional and complementary medicine to differentiate Malaysia's offerings.
'This gives us very high added value alongside our state-of-the-art quality that is affordable and accessible,' he said.
'Trust and compassion are synonymous with our healthcare tourism.'
The event also spotlighted the Flagship Medical Tourism Hospital Programme, naming four hospitals, National Heart Institute, Island Hospital Penang, Mahkota Medical Centre and Subang Jaya Medical Centre, as top contenders.
The Malaysia Healthcare Travel Council (MHTC), which is the organiser and lead agency behind the campaign, said these flagship institutions set benchmarks in clinical excellence, innovation and international patient services.
The campaign aligns with MHTC's RM12 billion revenue target by 2030, building on a 21% jump in medical tourism revenue in 2024 to RM2.72 billion.
Dzulkefly said Malaysia's role as chair of the Asean Health Ministers Meeting in 2026 will provide a platform to lead regional conversations on cross-border healthcare and equity.
Separately, he confirmed that Pasir Gudang Hospital is expected to reach 50% operational readiness by year-end, with full opening targeted for early 2026, pending staffing and equipment readiness.
He also welcomed the government's move to convert contract doctors to permanent service, saying it would boost morale and retention in the public healthcare system.
'This conversion is an incentive for them to stay with us. We will carry it out as soon as possible,' he said.
Renowned singer Datuk Sri Siti Nurhaliza was appointed MYMT 2026's ambassador to help extend Malaysia's medical tourism message to a broader audience, especially in neighbouring Indonesia where she has strong fan appeal.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Price labelling rule stays: MoH prioritises education over penalties
Price labelling rule stays: MoH prioritises education over penalties

New Straits Times

time2 hours ago

  • New Straits Times

Price labelling rule stays: MoH prioritises education over penalties

PUTRAJAYA: The Health Ministry (MoH) will continue focusing on education and awareness in enforcing the Price Control and Anti-Profiteering (Medicine Price Labelling) Order 2025, despite a pending judicial review application challenging the regulation. Health Minister Datuk Seri Dr Dzulkefly Ahmad said the ministry respected the legal process but was committed to ensuring smooth implementation of the order through educational enforcement. "We will continue with this approach to avoid enforcement gaps while the court process is ongoing," he told reporters after officiating the 2025 National Health Technology Assessment Conference and the 30th anniversary of the Malaysian Health Technology Assessment Section (MaHTAS) here today. The regulation, which came into force on May 1, mandates all private clinics and community pharmacies to display medicine prices on shelves, in catalogues or on written price lists, under the Price Control and Anti-Profiteering (Medicine Price Labelling) Order 2025. Dzulkefly was responding to reports that the Malaysian Medical Association (MMA) and seven other organisations have applied for leave to initiate a judicial review of the order. Among the applicants are the Sabah Private Practitioners Association (APPS), the Malaysian Association for the Advancement of Functional and Interdisciplinary Medicine (MAAFIM), the Malaysian Muslim Doctors Association (PERDIM), and the Federation of Private Medical Practitioners' Associations Malaysia (FPMPAM). On May 4, Dzulkefly had clarified that no fines or compounds would be issued during the first three months of enforcement, as the ministry's priority was on stakeholder education. As of now, neither MoH nor the Domestic Trade and Cost of Living Ministry has announced an extension to the grace period, which ends tomorrow (July 31). – BERNAMA

MoH open to reclassifying etomidate under Dangerous Drugs Act
MoH open to reclassifying etomidate under Dangerous Drugs Act

New Straits Times

time2 hours ago

  • New Straits Times

MoH open to reclassifying etomidate under Dangerous Drugs Act

PUTRAJAYA: The Health Ministry (MoH) is open to reviewing the proposal to list 'etomidate' under the Dangerous Drugs Act 1952 following reports of its frequent abuse, its minister Datuk Seri Dr Dzulkefly Ahmad said. He said that based on current clinical practices, the MoH was always ready to carry out evaluations or studies based on evidence presented by any party. Etomidate is currently listed under the Poisons Act 1952. "Any proposal can be considered, but at the end of the day, I look at the evidence base when evaluating something," he told a press conference after officiating the 2025 National Health Technology Assessment Conference and the 30th Anniversary Celebration of the Health Technology Assessment Section (MaHTAS) here today. Bandar Kuching MP Dr Kelvin Yii had before this urged the government to list etomidate under both the Poisons Act 1952 and the Dangerous Drugs Act 1952, citing reports of its fatal effects in Singapore. He said etomidate was an intravenous anaesthetic that had been misused as a recreational substance through vape products, often marketed as 'Kpods'. Kpods is a street term that usually refers to vape pods laced or contaminated with harmful chemicals or synthetic drugs, rather than just regular vape liquids like nicotine or flavouring. In a related development, Dzulkefly said the government is currently reviewing a proposal to ban e-cigarettes or vapes in the country. "I'm taking note, but I don't want to act hastily. We are taking this very seriously, and it needs to go through a thorough evaluation and consideration of legal and public health impacts," he said. – BERNAMA

MOH prioritises education in medicine price display enforcement amid legal challenge
MOH prioritises education in medicine price display enforcement amid legal challenge

The Sun

time7 hours ago

  • The Sun

MOH prioritises education in medicine price display enforcement amid legal challenge

PUTRAJAYA: The Ministry of Health (MOH) remains committed to an educational approach in enforcing the Price Control and Anti-Profiteering (Medicine Price Labelling) Order 2025, even as a judicial review application challenges the regulation. Health Minister Datuk Seri Dr Dzulkefly Ahmad emphasized that while the ministry respects the legal process, it will proceed with awareness initiatives to avoid gaps in enforcement. 'We will continue with this approach to avoid enforcement gaps while the court process is ongoing,' he said after officiating the 2025 National Health Technology Assessment Conference and the 30th anniversary of the Malaysian Health Technology Assessment Section (MaHTAS). The regulation, effective since May 1, requires private clinics and community pharmacies to display medicine prices on shelves, in catalogues, or through written price lists. The move aims to enhance transparency and prevent profiteering in the healthcare sector. Dr Dzulkefly addressed reports that the Malaysian Medical Association (MMA) and seven other organisations, including the Sabah Private Practitioners Association (APPS) and the Malaysian Muslim Doctors Association (PERDIM), have sought leave for a judicial review. On May 4, the minister clarified that no fines or penalties would be imposed during the initial three-month grace period, prioritizing stakeholder education instead. With the grace period ending on July 31, neither MOH nor the Ministry of Domestic Trade and Cost of Living (KPDN) has announced an extension. - Bernama

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store